

## Nutritional OUTLOOK

### Sami-Sabinsa Acquires Patent Rights for *Oroxylum indicum*, or Midnight Horror



Photo by J.M.Garg - Own work, CC BY-SA 3.0 via Wikimedia Commons

Jul 13, 2018

Sami-Sabinsa Group (East Windsor, NJ) has acquired the exclusive global marketing rights for two patents on *Oroxylum indicum*, an ingredient also known by the name *midnight horror*, and that may help alleviate symptoms of hyperglycemia associated with diabetes. Sabinsa obtained the patent rights from India R&D lab the Indian Institute of Chemical Technology (CSIR; Hyderabad, India).

Sabinsa has acquired two patents on *Oroxylum indicum*. The first (European patent #EP1986670) relates to use of the botanical's bioactive molecules oroxylin A, baicalein, and chrysin as alpha-glucosidase inhibitors. The second patent (U.S. patent #US7855200) relates to the use of those same constituents from *Oroxylum indicum* for treating gastric ulcers induced by aspirin.

Traditional Ayurvedic medicinal uses for *Oroxylum indicum* are varied and include curing gastric ulcer; applying a paste made from the bark in cases of mouth cancer, scabies, and other skin diseases; using the seed for relief of tonsil pain; and using the paste to kill maggots in animals.

## LATEST NEWS

### SAMI-SABINSA GROUP ACQUIRES EXCLUSIVE GLOBAL MARKETING RIGHTS FOR EUROPEAN AND USA PATENTS ON OROXYLUM INDICUM

The Sami-Sabinsa Group, which manufactures and markets phytonutrients and standardized herbal extracts, specialty fine chemicals, and organic intermediates used in the nutritional, cosmeceutical and food industries worldwide, has acquired exclusive global marketing rights for two patents on Oroxyllum indicum from one of India's longest-established R&D labs, the Indian Institute of Chemical Technology (CSIR), Hyderabad. The specific patents are European EP1986670 and USA US7855200.

Both patents disclose the biological use of bioactive compounds isolated from the plant Oroxyllum indicum. US7855200 discloses a method of treating gastric ulcers induced by aspirin using a composition containing Oroxylin A, Baicalein and Chrysin isolated from Oroxyllum indicum. Patent EP1986670 discloses the use of bioactive molecules Oroxylin A, Baicalein and Chrysin as a potent alpha-glucosidase inhibitor, used as a supplement or incorporated into pharmaceuticals, food products and health foods for treating hyperglycemia (elevated glucose levels). These bioactives have great potential in alleviating the symptoms of hyperglycemia associated with diabetes, obesity and other related conditions. The licensed invention relates to methods of using Oroxyllum indicum as a rich source for flavonoid

compounds having mucoprotective and antigestric ulcer properties, and containing Oroxylin A, Chrysin and Baicalein.

Dr. Muhammed Majeed, Founder & Chairman of the Sami-Sabinsa Group signed the agreement with Dr. D. Shailaja, Head of Business Development and Research Management & Senior Principal Scientist, CSIR - Indian Institute of Chemical Technology at



Sami Labs Bangalore, India office. "This accomplishment is another important milestone as it accelerates our mission to provide quality products that benefit human health throughout the world," said Dr. Majeed. "With our global presence, we will be able to bring this ancient remedy supported by modern research into the marketplace."

Oroxyllum indicum is a species of flowering plant belonging to the monotypic genus Oroxyllum and the family Bignoniaceae, customarily called a variety of intriguing names including midnight horror, Indian trumpet flower, broken bones, Indian caper, and tree of Damocles. Traditional Ayurvedic medicinal uses of Oroxyllum indicum include: the decoction of the bark from the plant taken for curing gastric ulcer; a paste made of the bark powder applied for mouth cancer, scabies, and other skin diseases; the seed is ground with fire-soot into a paste applied to the neck for quick relief of tonsil pain; a paste made of the bark applied to the wounds of animals to kill maggots; and a decoction of the bark is given to animals for de-worming. The plant is also claimed to have anti-cancer properties.

## Sami-Sabinsa Group acquires exclusive global marketing rights

The ingredients manufacturer has acquired the marketing rights for *Oroxylum indicum*, a species of flowering plant. 6-July-2018



L-R: Dr D. Shailaja and Dr Muhammed Majeed

The Sami-Sabinsa Group, which manufactures and markets phytonutrients and standardised herbal extracts, specialty fine chemicals and organic intermediates used in the nutritional, cosmeceutical and food industries worldwide, has acquired exclusive global marketing rights for two patents on *Oroxylum indicum* from one of India's longest-established R&D labs, the Indian Institute of Chemical Technology (CSIR), Hyderabad.

Both patents disclose the biological use of bioactive compounds isolated from the plant *Oroxylum indicum*. The US patent discloses a method of

treating gastric ulcers induced by aspirin using a composition containing Oroxylin A, Baicalein and Chrysin isolated from *Oroxylum indicum*.

The EU Patent discloses the use of bioactive molecules Oroxylin A, Baicalein and Chrysin as a potent alpha-glucosidase inhibitor, used as a supplement or incorporated into pharmaceuticals, food products and health foods for treating hyperglycemia (elevated glucose levels).

These bioactives have great potential in alleviating the symptoms of hyperglycemia associated with diabetes, obesity and other related conditions. The licensed invention relates to methods of using *Oroxylum indicum* as a rich source for flavonoid compounds having mucoprotective and antigestric ulcer properties, and containing Oroxylin A, Chrysin and Baicalein.

Dr Muhammed Majeed, founder and chairman of the Sami-Sabinsa Group signed the agreement with Dr D. Shailaja, Head of Business Development and Research Management & Senior Principal Scientist, CSIR - Indian Institute of Chemical Technology at Sami Labs Bangalore, India office.

"This accomplishment is another important milestone as it accelerates our mission to provide quality products that benefit human health throughout the world," said Dr Majeed.

"With our global presence, we will be able to bring this ancient remedy supported by modern research into the marketplace."

*Oroxylum indicum* is a species of flowering plant belonging to the monotypic genus *Oroxylum* and the family Bignoniaceae, customarily called a variety of intriguing names including midnight horror, Indian trumpet flower, broken bones, Indian caper, and tree of Damocles.

Traditional Ayurvedic medicinal uses of *Oroxylum indicum* include: the decoction of the bark from the plant taken for curing gastric ulcer; a paste made of the bark powder applied for mouth cancer, scabies, and other skin diseases; the seed is ground with fire-soot into a paste applied to the neck for quick relief of tonsil pain; a paste made of the bark applied to the wounds of animals to kill maggots; and a decoction of the bark is given to animals for deworming. The plant is also claimed to have anti-cancer properties.

The specific patents are European EP1986670 and USA Us7855200.



## Sami Labs acquires global marketing rights for Oroxyllum Indicum from CSIR

*The plant with various medicinal uses has been patented by the CSIR-Indian Institute of Chemical Technology and now its marketing rights for the US and European markets have been acquired by the Sami Labs*

By BioVoice Correspondent - June 21, 2018



Dr. Muhammed Majeed, Founder & Chairman Sami-Sabinsa Group with Dr. D. Shailaja, Head Business Development and Research Management & Senior Principal Scientist, CSIR - Indian Institute of Chemical Technology.

**Bengaluru:** Sami Labs has acquired the exclusive Global Marketing Rights for European and USA patents on Oroxyllum Indicum from the Council for Scientific and Industrial Research (CSIR) – Indian Institute of Chemical Technology, Hyderabad.

Oroxyllum Indicum is a species of flowering plant belonging to the monotypic genus Oroxyllum and the family Bignoniaceae, are commonly called midnight horror, Indian trumpet flower, broken bones, Indian caper, or tree of Damocles.

Among the various medicinal uses, the decoction of the bark from the plant is taken for curing gastric ulcer and a paste made of the bark powder is applied for mouth cancer, scabies and other skin diseases. The seed is ground with fire-soot and the paste applied to the neck for quick relief of tonsil pain. Also, a paste made of the bark is applied to the wounds of animals to kill maggots. Decoction of the bark is given to animals for de-worming. The plant is also claimed to have anti-cancer properties.

Dr Muhammed Majeed, Founder & Chairman Sami-Sabinsa Group signed the agreement with Dr D Shailaja, Head of Business Development and Research Management & Senior Principal Scientist, CSIR – Indian Institute of Chemical Technology at Sami Labs office Bengaluru.

"This achievement is a milestone in our collaboration as it accelerates our mission to provide quality products across the globe," said Dr Majeed.

Sami Labs Limited is a leading producer of nutraceuticals, cosmeceuticals, standardized herbal extracts, fine chemicals, specialty chemicals and probiotics. The Government of India honored Sami Labs Limited with the National Award for Quality Products (Basic Drugs) in the year 1994 and the Prestigious DSIR award in the year 2002.

The CSIR-Indian Institute of Chemical Technology (CSIR-IICT) is one of the oldest National Laboratories under the Council of Scientific & Industrial Research (CSIR). CSIR-IICT during its seventy-year journey has made its mark as a dynamic, innovative and result in oriented R&D organization.

21/06/2018 – NuFFoods Spectrum



## Sami Labs acquires exclusive patent marketing rights for Oroxyllum Indicum

21 June, 2018



Sami Labs, which manufactures and markets phytonutrients and standardized herbal extracts, specialty fine chemicals, and organic intermediates used in the nutritional, dermaceutical and food industries, has acquired exclusive Global Marketing Rights for European and USA patents on Oroxyllum Indicum from CSIR – Indian Institute of Chemical Technology, Hyderabad.

Dr. Muhammed Majeed, Founder & Chairman Sami-Sabinsa Group signed the agreement with Dr. D. Shailaja, Head of Business Development and Research Management & Senior Principal Scientist, CSIR - Indian Institute of Chemical Technology today at Sami Labs office Bangalore.

This achievement is a milestone in our collaboration as it accelerates our mission to provide quality products across the globe, said Dr. Majeed.